|
1.
|
Zimmermann J, Krauthausen M, Hofer MJ, Heneka MT, Campbell IL, Müller M. CNS-Targeted Production of IL-17A Induces Glial Activation, Microvascular Pathology and Enhances the Neuroinflammatory Response to Systemic Endotoxemia. PLoS One. 2013; 8(2):e57307.
|
|
|
|
|
2.
|
Okroglic S, Widmann CN, Urbach H, Scheltens P, Heneka MT. Clinical symptoms and risk factors in cerebral microangiopathy patients. PLoS One. 2013; 8(2):e53455.
|
|
|
|
|
3.
|
van der Zee J, Gijselinck I, Dillen L, Van Langenhove T, Theuns J, Engelborghs S, Philtjens S, Vandenbulcke M, Sleegers K, Sieben A, Bäumer V, Maes G, Corsmit E, Borroni B, Padovani A, Archetti S, Perneczky R, Diehl-Schmid J, de Mendonça A, Miltenberger-Miltenyi G, Pereira S, Pimentel J, Nacmias B, Bagnoli S, Sorbi S, Graff C, Chiang HH, Westerlund M, Sanchez-Valle R, Llado A, Gelpi E, Santana I, Almeida MR, Santiago B, Frisoni G, Zanetti O, Bonvicini C, Synofzik M, Maetzler W, Vom Hagen JM, Schöls L, Heneka MT, Jessen F, Matej R, Parobkova E, Kovacs GG, Ströbel T, Sarafov S, Tournev I, Jordanova A, Danek A, Arzberger T, Fabrizi GM, Testi S, Salmon E, Santens P, Martin JJ, Cras P, Vandenberghe R, De Deyn PP, Cruts M, Van Broeckhoven C, van der Zee J, Gijselinck I, Dillen L, Van Langenhove T, Theuns J, Philtjens S, Sleegers K, Bäumer V, Maes G, Corsmit E, Cruts M, Van Broeckhoven C, van der Zee J, Gijselinck I, Dillen L, Van Langenhove T, Philtjens S, Theuns J, Sleegers K, Bäumer V, Maes G, Cruts M, Van Broeckhoven C, Engelborghs S, De Deyn PP, Cras P, Engelborghs S, De Deyn PP, Vandenbulcke M, Vandenbulcke M, Borroni B, Padovani A, Archetti S, Perneczky R, Diehl-Schmid J, Synofzik M, Maetzler W, Müller Vom Hagen J, Schöls L, Synofzik M, Maetzler W, Müller Vom Hagen J, Schöls L, Heneka MT, Jessen F, Ramirez A, Kurzwelly D, Sachtleben C, Mairer W, de Mendonça A, Miltenberger-Miltenyi G, Pereira S, Firmo C, Pimentel J, Sanchez-Valle R, Llado A, Antonell A, Molinuevo J, Gelpi E, Graff C, Chiang HH, Westerlund M, Graff C, Kinhult Ståhlbom A, Thonberg H, Nennesmo I, Börjesson-Hanson A, Nacmias B, Bagnoli S, Sorbi S, Bessi V, Piaceri I, Santana I, Santiago B, Santana I, Helena Ribeiro M, Rosário Almeida M, Oliveira C, Massano J, Garret C, Pires P, Frisoni G, Zanetti O, Bonvicini C, Sarafov S, Tournev I, Jordanova A, Tournev I, Kovacs GG, Ströbel T, Heneka MT, Jessen F, Ramirez A, Kurzwelly D, Sachtleben C, Mairer W, Jessen F, Matej R, Parobkova E, Danel A, Arzberger T, Maria Fabrizi G, Testi S, Ferrari S, Cavallaro T, Salmon E, Santens P, Cras P. A Pan-European Study of the C9orf72 Repeat Associated with FTLD: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. Hum Mutat. 2013 Feb; 34(2):363-73.
|
|
|
|
|
4.
|
Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, Gelpi E, Halle A, Korte M, Latz E, Golenbock DT. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013 Jan 31; 493(7434):674-8.
|
|
|
|
|
5.
|
Kummer MP, Vogl T, Axt D, Griep A, Vieira-Saecker A, Jessen F, Gelpi E, Roth J, Heneka MT. Mrp14 Deficiency Ameliorates Amyloid ß Burden by Increasing Microglial Phagocytosis and Modulation of Amyloid Precursor Protein Processing. J Neurosci. 2012 Dec 5; 32(49):17824-9.
|
|
|
|
|
6.
|
Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT. PPAR?/RXRa-Induced and CD36-Mediated Microglial Amyloid-ß Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice. J Neurosci. 2012 Nov 28; 32(48):17321-31.
|
|
|
|
|
7.
|
Semmler A, Widmann CN, Okulla T, Urbach H, Kaiser M, Widman G, Mormann F, Weide J, Fliessbach K, Hoeft A, Jessen F, Putensen C, Heneka MT. Persistent cognitive impairment, hippocampal atrophy and EEG changes in sepsis survivors. J Neurol Neurosurg Psychiatry. 2013 Jan; 84(1):62-9.
|
|
|
|
|
8.
|
Scheef L, Spottke A, Daerr M, Joe A, Striepens N, Kölsch H, Popp J, Daamen M, Gorris D, Heneka MT, Boecker H, Biersack HJ, Maier W, Schild HH, Wagner M, Jessen F. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology. 2012 Sep 25; 79(13):1332-9.
|
|
|
|
|
9.
|
Hammerschmidt T, Kummer MP, Terwel D, Martinez A, Gorji A, Pape HC, Rommelfanger KS, Schroeder JP, Stoll M, Schultze J, Weinshenker D, Heneka MT. Selective Loss of Noradrenaline Exacerbates Early Cognitive Dysfunction and Synaptic Deficits in APP/PS1 Mice. Biol Psychiatry. 2013 Mar 1; 73(5):454-63.
|
|
|
|
|
10.
|
Semmler A, Okulla T, Kaiser M, Seifert B, Heneka MT. Long-term neuromuscular sequelae of critical illness. J Neurol. 2013 Jan; 260(1):151-7.
|
|
|
|
|
11.
|
Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, Fischer W, Steiner F, Lindauer E, Otto M, Dreyhaupt J, Grehl T, Hermann A, Winkler AS, Bogdahn U, Benecke R, Schrank B, Wessig C, Grosskreutz J, Ludolph AC. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One. 2012; 7(6):e37885.
|
|
|
|
|
12.
|
Rapic S, Backes H, Viel T, Kummer MP, Monfared P, Neumaier B, Vollmar S, Hoehn M, Van der Linden A, Heneka MT, Jacobs AH. Imaging microglial activation and glucose consumption in a mouse model of Alzheimer's disease. Neurobiol Aging. 2013 Jan; 34(1):351-4.
|
|
|
|
|
13.
|
Parpura V, Heneka MT, Montana V, Oliet SH, Schousboe A, Haydon PG, Stout RF, Spray DC, Reichenbach A, Pannicke T, Pekny M, Pekna M, Zorec R, Verkhratsky A. Glial cells in (patho)physiology. J Neurochem. 2012 Apr; 121(1):4-27.
|
|
|
|
|
14.
|
Kummer MP, Hülsmann C, Hermes M, Axt D, Heneka MT. Nitric Oxide Decreases the Enzymatic Activity of Insulin Degrading Enzyme in APP/PS1 Mice. J Neuroimmune Pharmacol. 2012 Mar; 7(1):165-72.
|
|
|
|
|
15.
|
Liu S, Liu Y, Hao W, Wolf L, Kiliaan AJ, Penke B, Rübe CE, Walter J, Heneka MT, Hartmann T, Menger MD, Fassbender K. TLR2 Is a Primary Receptor for Alzheimer's Amyloid ß Peptide To Trigger Neuroinflammatory Activation. J Immunol. 2012 Feb 1; 188(3):1098-107.
|
|
|
|
|
16.
|
Heneka MT, Reyes-Irisarri E, Hüll M, Kummer MP. Impact and Therapeutic Potential of PPARs in Alzheimer's Disease. Curr Neuropharmacol. 2011 Dec; 9(4):643-50.
|
|
|
|
|
17.
|
Krauthausen M, Ellis SL, Zimmermann J, Sarris M, Wakefield D, Heneka MT, Campbell IL, Müller M. Opposing roles for CXCR3 signaling in central nervous system versus ocular inflammation mediated by the astrocyte-targeted production of IL-12. Am J Pathol. 2011 Nov; 179(5):2346-59.
|
|
|
|
|
18.
|
Kummer MP, Hermes M, Delekarte A, Hammerschmidt T, Kumar S, Terwel D, Walter J, Pape HC, König S, Roeber S, Jessen F, Klockgether T, Korte M, Heneka MT. Nitration of tyrosine 10 critically enhances amyloid ß aggregation and plaque formation. Neuron. 2011 Sep 8; 71(5):833-44.
|
|
|
|
|
19.
|
Mildner A, Schlevogt B, Kierdorf K, Böttcher C, Erny D, Kummer MP, Quinn M, Brück W, Bechmann I, Heneka MT, Priller J, Prinz M. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J Neurosci. 2011 Aug 3; 31(31):11159-71.
|
|
|
|
|
20.
|
Juckel G, Manitz MP, Brüne M, Friebe A, Heneka MT, Wolf RJ. Microglial activation in a neuroinflammational animal model of schizophrenia--a pilot study. Schizophr Res. 2011 Sep; 131(1-3):96-100.
|
|
|
|
|
21.
|
Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Lladó A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O'Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schröder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 2011 Jul; 7(4):386-395.e6.
|
|
|
|
|
22.
|
Terwel D, Löschmann YN, Schmidt HH, Schöler HR, Cantz T, Heneka MT. Neuroinflammatory and behavioural changes in the Atp7B mutant mouse model of Wilson's disease. J Neurochem. 2011 Jul; 118(1):105-12.
|
|
|
|
|
23.
|
Terwel D, Steffensen KR, Verghese PB, Kummer MP, Gustafsson JÅ, Holtzman DM, Heneka MT. Critical role of astroglial apolipoprotein E and liver X receptor-a expression for microglial Aß phagocytosis. J Neurosci. 2011 May 11; 31(19):7049-59.
|
|
|
|
|
24.
|
Kumar S, Rezaei-Ghaleh N, Terwel D, Thal DR, Richard M, Hoch M, Mc Donald JM, Wüllner U, Glebov K, Heneka MT, Walsh DM, Zweckstetter M, Walter J. Extracellular phosphorylation of the amyloid ß-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. EMBO J. 2011 Jun 1; 30(11):2255-65.
|
|
|
|
|
25.
|
Heneka MT, Kummer MP, Weggen S, Bulic B, Multhaup G, Münter L, Hüll M, Pflanzner T, Pietrzik CU. Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease. Curr Alzheimer Res. 2011 Mar; 8(2):115-31.
|
|
|
|
|
26.
|
Perez Nievas BG, Hammerschmidt T, Kummer MP, Terwel D, Leza JC, Heneka MT. Restraint stress increases neuroinflammation independently of amyloid ß levels in amyloid precursor protein/PS1 transgenic mice. J Neurochem. 2011 Jan; 116(1):43-52.
|
|
|
|
|
27.
|
Jardanhazi-Kurutz D, Kummer MP, Terwel D, Vogel K, Thiele A, Heneka MT. Distinct adrenergic system changes and neuroinflammation in response to induced locus ceruleus degeneration in APP/PS1 transgenic mice. Neuroscience. 2011 Mar 10; 176:396-407.
|
|
|
|
|
28.
|
Rey NL, Jardanhazi-Kurutz D, Terwel D, Kummer MP, Jourdan F, Didier A, Heneka MT. Locus coeruleus degeneration exacerbates olfactory deficits in APP/PS1 transgenic mice. Neurobiol Aging. 2012 Feb; 33(2):426.e1-426.e11.
|
|
|
|
|
29.
|
Fleisher-Berkovich S, Filipovich-Rimon T, Ben-Shmuel S, Hülsmann C, Kummer MP, Heneka MT. Distinct modulation of microglial amyloid ß phagocytosis and migration by neuropeptides (i). J Neuroinflammation. 2010; 7:61.
|
|
|
|
|
30.
|
Tamboli IY, Barth E, Christian L, Siepmann M, Kumar S, Singh S, Tolksdorf K, Heneka MT, Lütjohann D, Wunderlich P, Walter J. Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion. J Biol Chem. 2010 Nov 26; 285(48):37405-14.
|
|
|
|
|
31.
|
Heneka MT, O'Banion MK, Terwel D, Kummer MP. Neuroinflammatory processes in Alzheimer's disease. J Neural Transm. 2010 Aug; 117(8):919-47.
|
|
|
|
|
32.
|
Heneka MT. [Course modifying therapy of Alzheimer's dementia]. Nervenarzt. 2010 Jul; 81(7):807-8, 810-4.
|
|
|
|
|
33.
|
Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D, Jardanhazi-Kurutz D, Walter J, Kirchhoff F, Hanisch UK, Kummer MP. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A. 2010 Mar 30; 107(13):6058-63.
|
|
|
|
|
34.
|
Jardanhazi-Kurutz D, Kummer MP, Terwel D, Vogel K, Dyrks T, Thiele A, Heneka MT. Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem Int. 2010 Nov; 57(4):375-82.
|
|
|
|
|
35.
|
Schlachetzki JC, Fiebich BL, Haake E, de Oliveira AC, Candelario-Jalil E, Heneka MT, Hüll M. Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE2 in primary rat microglia. J Neuroinflammation. 2010; 7:2.
|
|
|
|
|
36.
|
Jäger S, Leuchtenberger S, Martin A, Czirr E, Wesselowski J, Dieckmann M, Waldron E, Korth C, Koo EH, Heneka M, Weggen S, Pietrzik CU. alpha-secretase mediated conversion of the amyloid precursor protein derived membrane stub C99 to C83 limits Abeta generation. J Neurochem. 2009 Dec; 111(6):1369-82.
|
|
|
|
|
37.
|
Heneka MT, Rodríguez JJ, Verkhratsky A. Neuroglia in neurodegeneration. Brain Res Rev. 2010 May; 63(1-2):189-211.
|
|
|
|
|
38.
|
Weberpals M, Hermes M, Hermann S, Kummer MP, Terwel D, Semmler A, Berger M, Schäfers M, Heneka MT. NOS2 gene deficiency protects from sepsis-induced long-term cognitive deficits. J Neurosci. 2009 Nov 11; 29(45):14177-84.
|
|
|
|
|
39.
|
Papi A, Tatenhorst L, Terwel D, Hermes M, Kummer MP, Orlandi M, Heneka MT. PPARgamma and RXRgamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models. J Neurochem. 2009 Jun; 109(6):1779-90.
|
|
|
|
|
40.
|
Heneka MT. Noradrenergic denervation facilitates the release of acetylcholine and serotonin in the hippocampus: towards a mechanism underlying upregulations described in MCI patients. Exp Neurol. 2009 Jun; 217(2):237-9.
|
|
|
|
|
41.
|
Tamboli IY, Prager K, Thal DR, Thelen KM, Dewachter I, Pietrzik CU, St George-Hyslop P, Sisodia SS, De Strooper B, Heneka MT, Filippov MA, Müller U, van Leuven F, Lütjohann D, Walter J. Loss of gamma-secretase function impairs endocytosis of lipoprotein particles and membrane cholesterol homeostasis. J Neurosci. 2008 Nov 12; 28(46):12097-106.
|
|
|
|
|
42.
|
Semmler A, Hermann S, Mormann F, Weberpals M, Paxian SA, Okulla T, Schäfers M, Kummer MP, Klockgether T, Heneka MT. Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism. J Neuroinflammation. 2008; 5:38.
|
|
|
|
|
43.
|
Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics. 2008 Jul; 5(3):481-9.
|
|
|
|
|
44.
|
Winkeler A, Waerzeggers Y, Klose A, Monfared P, Thomas AV, Schubert M, Heneka MT, Jacobs AH. Imaging noradrenergic influence on amyloid pathology in mouse models of Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2008 Mar; 35 Suppl 1:S107-13.
|
|
|
|
|
45.
|
Seufert S, Coras R, Tränkle C, Zlotos DP, Blümcke I, Tatenhorst L, Heneka MT, Hahnen E. PPAR Gamma Activators: Off-Target Against Glioma Cell Migration and Brain Invasion. PPAR Res. 2008; 2008:513943.
|
|
|
|
|
46.
|
Kummer MP, Heneka MT. PPARs in Alzheimer's Disease. PPAR Res. 2008; 2008:403896.
|
|
|
|
|
47.
|
Tatenhorst L, Hahnen E, Heneka MT. Peroxisome Proliferator-Activated Receptors (PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors. PPAR Res. 2008; 2008:204514.
|
|
|
|
|
48.
|
Jiang Q, Heneka M, Landreth GE. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs. 2008; 22(1):1-14.
|
|
|
|
|
49.
|
Heneka MT, Landreth GE, Hüll M. Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Nat Clin Pract Neurol. 2007 Sep; 3(9):496-504.
|
|
|
|
|
50.
|
Winkeler A, Sena-Esteves M, Paulis LE, Li H, Waerzeggers Y, Rückriem B, Himmelreich U, Klein M, Monfared P, Rueger MA, Heneka M, Vollmar S, Hoehn M, Fraefel C, Graf R, Wienhard K, Heiss WD, Jacobs AH. Switching on the lights for gene therapy. PLoS One. 2007; 2(6):e528.
|
|
|
|
|
51.
|
Rueger MA, Kracht LW, Hilker R, Thiel A, Sobesky J, Winkeler A, Thomas AV, Heneka MT, Graf R, Herholz K, Heiss WD, Jacobs AH. Role of in vivo imaging of the central nervous system for developing novel drugs. Q J Nucl Med Mol Imaging. 2007 Jun; 51(2):164-81.
|
|
|
|
|
52.
|
Heneka MT, Landreth GE. PPARs in the brain. Biochim Biophys Acta. 2007 Aug; 1771(8):1031-45.
|
|
|
|
|
53.
|
Kummer C, Winkeler A, Dittmar C, Bauer B, Rueger MA, Rueckriem B, Heneka MT, Vollmar S, Wienhard K, Fraefel C, Heiss WD, Jacobs AH. Multitracer positron emission tomographic imaging of exogenous gene expression mediated by a universal herpes simplex virus 1 amplicon vector. Mol Imaging. 2007 May-Jun; 6(3):181-92.
|
|
|
|
|
54.
|
Jacobs AH, Rueger MA, Winkeler A, Li H, Vollmar S, Waerzeggers Y, Rueckriem B, Kummer C, Dittmar C, Klein M, Heneka MT, Herrlinger U, Fraefel C, Graf R, Wienhard K, Heiss WD. Imaging-guided gene therapy of experimental gliomas. Cancer Res. 2007 Feb 15; 67(4):1706-15.
|
|
|
|
|
55.
|
Semmler A, Frisch C, Debeir T, Ramanathan M, Okulla T, Klockgether T, Heneka MT. Long-term cognitive impairment, neuronal loss and reduced cortical cholinergic innervation after recovery from sepsis in a rodent model. Exp Neurol. 2007 Apr; 204(2):733-40.
|
|
|
|
|
56.
|
Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol. 2007 Mar; 184(1-2):69-91.
|
|
|
|
|
57.
|
Thees C, Kaiser M, Scholz M, Semmler A, Heneka MT, Baumgarten G, Hoeft A, Putensen C. Cerebral haemodynamics and carbon dioxide reactivity during sepsis syndrome. Crit Care. 2007; 11(6):R123.
|
|
|
|
|
58.
|
Wahle T, Thal DR, Sastre M, Rentmeister A, Bogdanovic N, Famulok M, Heneka MT, Walter J. GGA1 is expressed in the human brain and affects the generation of amyloid beta-peptide. J Neurosci. 2006 Dec 6; 26(49):12838-46.
|
|
|
|
|
59.
|
Grommes C, Landreth GE, Sastre M, Beck M, Feinstein DL, Jacobs AH, Schlegel U, Heneka MT. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol Pharmacol. 2006 Nov; 70(5):1524-33.
|
|
|
|
|
60.
|
Ambrée O, Leimer U, Herring A, Görtz N, Sachser N, Heneka MT, Paulus W, Keyvani K. Reduction of amyloid angiopathy and Abeta plaque burden after enriched housing in TgCRND8 mice: involvement of multiple pathways. Am J Pathol. 2006 Aug; 169(2):544-52.
|
|
|
|
|
61.
|
Kalinin S, Gavrilyuk V, Polak PE, Vasser R, Zhao J, Heneka MT, Feinstein DL. Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging. 2007 Aug; 28(8):1206-14.
|
|
|
|
|
62.
|
Sundararajan S, Jiang Q, Heneka M, Landreth G. PPARgamma as a therapeutic target in central nervous system diseases. Neurochem Int. 2006 Jul; 49(2):136-44.
|
|
|
|
|
63.
|
Sastre M, Klockgether T, Heneka MT. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci. 2006 Apr-May; 24(2-3):167-76.
|
|
|
|
|
64.
|
Heneka MT, Ramanathan M, Jacobs AH, Dumitrescu-Ozimek L, Bilkei-Gorzo A, Debeir T, Sastre M, Galldiks N, Zimmer A, Hoehn M, Heiss WD, Klockgether T, Staufenbiel M. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci. 2006 Feb 1; 26(5):1343-54.
|
|
|
|
|
65.
|
Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, Walter J, Klockgether T, van Leuven F, Heneka MT. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A. 2006 Jan 10; 103(2):443-8.
|
|
|
|
|
66.
|
Hüll M, Berger M, Heneka M. Disease-modifying therapies in Alzheimer's disease: how far have we come? Drugs. 2006; 66(16):2075-93.
|
|
|
|
|
67.
|
Klotz L, Schmidt M, Giese T, Sastre M, Knolle P, Klockgether T, Heneka MT. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol. 2005 Oct 15; 175(8):4948-55.
|
|
|
|
|
68.
|
Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T, Van Leuven F. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation. 2005 Oct 7; 2:22.
|
|
|
|
|
69.
|
Semmler A, Okulla T, Sastre M, Dumitrescu-Ozimek L, Heneka MT. Systemic inflammation induces apoptosis with variable vulnerability of different brain regions. J Chem Neuroanat. 2005 Oct; 30(2-3):144-57.
|
|
|
|
|
70.
|
Schütz B, Reimann J, Dumitrescu-Ozimek L, Kappes-Horn K, Landreth GE, Schürmann B, Zimmer A, Heneka MT. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci. 2005 Aug 24; 25(34):7805-12.
|
|
|
|
|
71.
|
Tamboli IY, Prager K, Barth E, Heneka M, Sandhoff K, Walter J. Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. J Biol Chem. 2005 Jul 29; 280(30):28110-7.
|
|
|
|
|
72.
|
Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain. 2005 Jun; 128(Pt 6):1442-53.
|
|
|
|
|
73.
|
Rueger MA, Winkeler A, Miletic H, Kaestle C, Richter R, Schneider G, Hilker R, Heneka MT, Ernestus RI, Hampl JA, Fraefel C, Jacobs AH. Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors. Gene Ther. 2005 Apr; 12(7):588-96.
|
|
|
|
|
74.
|
Grommes C, Landreth GE, Schlegel U, Heneka MT. The nonthiazolidinedione tyrosine-based peroxisome proliferator-activated receptor gamma ligand GW7845 induces apoptosis and limits migration and invasion of rat and human glioma cells. J Pharmacol Exp Ther. 2005 May; 313(2):806-13.
|
|
|
|
|
75.
|
Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 2004 Jul; 5(7):419-29.
|
|
|
|
|
76.
|
Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem. 2004 Jan; 88(2):494-501.
|
|
|
|
|
77.
|
Schmidt S, Moric E, Schmidt M, Sastre M, Feinstein DL, Heneka MT. Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J Leukoc Biol. 2004 Mar; 75(3):478-85.
|
|
|
|
|
78.
|
Pedraza CE, Baltrons MA, Heneka MT, García A. Interleukin-1 beta and lipopolysaccharide decrease soluble guanylyl cyclase in brain cells: NO-independent destabilization of protein and NO-dependent decrease of mRNA. J Neuroimmunol. 2003 Nov; 144(1-2):80-90.
|
|
|
|
|
79.
|
Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, Heneka MT. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci. 2003 Oct 29; 23(30):9796-804.
|
|
|
|
|
80.
|
Galea E, Heneka MT, Dello Russo C, Feinstein DL. Intrinsic regulation of brain inflammatory responses. Cell Mol Neurobiol. 2003 Oct; 23(4-5):625-35.
|
|
|
|
|
81.
|
Klotz L, Sastre M, Kreutz A, Gavrilyuk V, Klockgether T, Feinstein DL, Heneka MT. Noradrenaline induces expression of peroxisome proliferator activated receptor gamma (PPARgamma) in murine primary astrocytes and neurons. J Neurochem. 2003 Aug; 86(4):907-16.
|
|
|
|
|
82.
|
Heneka MT, Gavrilyuk V, Landreth GE, O'Banion MK, Weinberg G, Feinstein DL. Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression. J Neurochem. 2003 Apr; 85(2):387-98.
|
|
|
|
|
83.
|
Harzheim M, Altenschmidt M, Heneka MT, Schröder R, Klockgether T, Schmidt S. IFN-beta1a (Rebif) modifies the expression of microfilament-associated cell-cell contacts in C6 glioma cells. J Interferon Cytokine Res. 2003 Feb; 23(2):83-9.
|
|
|
|
|
84.
|
Feinstein DL, Heneka MT, Gavrilyuk V, Dello Russo C, Weinberg G, Galea E. Noradrenergic regulation of inflammatory gene expression in brain. Neurochem Int. 2002 Nov; 41(5):357-65.
|
|
|
|
|
85.
|
Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem. 2002 Aug; 82(3):615-24.
|
|
|
|
|
86.
|
Baltrons MA, Pedraza CE, Heneka MT, García A. Beta-amyloid peptides decrease soluble guanylyl cyclase expression in astroglial cells. Neurobiol Dis. 2002 Jul; 10(2):139-49.
|
|
|
|
|
87.
|
Gavrilyuk V, Dello Russo C, Heneka MT, Pelligrino D, Weinberg G, Feinstein DL. Norepinephrine increases I kappa B alpha expression in astrocytes. J Biol Chem. 2002 Aug 16; 277(33):29662-8.
|
|
|
|
|
88.
|
Zander T, Kraus JA, Grommes C, Schlegel U, Feinstein D, Klockgether T, Landreth G, Koenigsknecht J, Heneka MT. Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J Neurochem. 2002 Jun; 81(5):1052-60.
|
|
|
|
|
89.
|
Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol. 2002 Jun; 51(6):694-702.
|
|
|
|
|
90.
|
Heneka MT, Galea E, Gavriluyk V, Dumitrescu-Ozimek L, Daeschner J, O'Banion MK, Weinberg G, Klockgether T, Feinstein DL. Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. J Neurosci. 2002 Apr 1; 22(7):2434-42.
|
|
|
|
|
91.
|
Murphy P, Sharp A, Shin J, Gavrilyuk V, Dello Russo C, Weinberg G, Sharp FR, Lu A, Heneka MT, Feinstein DL. Suppressive effects of ansamycins on inducible nitric oxide synthase expression and the development of experimental autoimmune encephalomyelitis. J Neurosci Res. 2002 Feb 15; 67(4):461-70.
|
|
|
|
|
92.
|
Landreth GE, Heneka MT. Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol Aging. 2001 Nov-Dec; 22(6):937-44.
|
|
|
|
|
93.
|
Heneka MT, Wiesinger H, Dumitrescu-Ozimek L, Riederer P, Feinstein DL, Klockgether T. Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J Neuropathol Exp Neurol. 2001 Sep; 60(9):906-16.
|
|
|
|
|
94.
|
Heneka MT, Sharp A, Murphy P, Lyons JA, Dumitrescu L, Feinstein DL. The heat shock response reduces myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in mice. J Neurochem. 2001 Apr; 77(2):568-79.
|
|
|
|
|
95.
|
Heneka MT, Feinstein DL. Expression and function of inducible nitric oxide synthase in neurons. J Neuroimmunol. 2001 Mar 1; 114(1-2):8-18.
|
|
|
|
|
96.
|
Heneka MT, Landreth GE, Feinstein DL. Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease. Ann Neurol. 2001 Feb; 49(2):276.
|
|
|
|
|
97.
|
Heneka MT, Klockgether T, Feinstein DL. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci. 2000 Sep 15; 20(18):6862-7.
|
|
|
|
|
98.
|
Heneka MT, Sharp A, Klockgether T, Gavrilyuk V, Feinstein DL. The heat shock response inhibits NF-kappaB activation, nitric oxide synthase type 2 expression, and macrophage/microglial activation in brain. J Cereb Blood Flow Metab. 2000 May; 20(5):800-11.
|
|
|
|
|
99.
|
Heneka MT, Dumitrescu L, Löschmann PA, Wüllner U, Klockgether T. Temporal, regional, and cell-specific changes of iNOS expression after intrastriatal microinjection of interferon gamma and bacterial lipopolysaccharide. J Chem Neuroanat. 2000 Apr; 18(4):167-79.
|
|
|
|
|
100.
|
Heneka MT, Feinstein DL, Galea E, Gleichmann M, Wüllner U, Klockgether T. Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J Neuroimmunol. 1999 Dec; 100(1-2):156-68.
|
|
|
|
|
101.
|
Heneka MT, Schmidlin A, Wiesinger H. Induction of argininosuccinate synthetase in rat brain glial cells after striatal microinjection of immunostimulants. J Cereb Blood Flow Metab. 1999 Aug; 19(8):898-907.
|
|
|
|
|
102.
|
Roller A, Bähr OR, Streffer J, Winter S, Heneka M, Deininger M, Meyermann R, Naumann U, Gulbins E, Weller M. Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP. Biochem Biophys Res Commun. 1999 Jun 16; 259(3):600-5.
|
|
|
|
|
103.
|
Wüllner U, Seyfried J, Groscurth P, Beinroth S, Winter S, Gleichmann M, Heneka M, Löschmann P, Schulz JB, Weller M, Klockgether T. Glutathione depletion and neuronal cell death: the role of reactive oxygen intermediates and mitochondrial function. Brain Res. 1999 Apr 24; 826(1):53-62.
|
|
|
|
|
104.
|
Rieger J, Ständer M, Löschmann PA, Heneka M, Dichgans J, Klockgether T, Weller M. Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF-beta, dexamethasone, and p53 gene transfer. Oncogene. 1998 Nov 5; 17(18):2323-32.
|
|
|
|
|
105.
|
Schulz JB, Weller M, Matthews RT, Heneka MT, Groscurth P, Martinou JC, Lommatzsch J, von Coelln R, Wüllner U, Löschmann PA, Beal MF, Dichgans J, Klockgether T. Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. Cell Death Differ. 1998 Oct; 5(10):847-57.
|
|
|
|
|
106.
|
Ständer M, Naumann U, Dumitrescu L, Heneka M, Löschmann P, Gulbins E, Dichgans J, Weller M. Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther. 1998 Sep; 5(9):1187-94.
|
|
|
|
|
107.
|
Heneka MT, Löschmann PA, Gleichmann M, Weller M, Schulz JB, Wüllner U, Klockgether T. Induction of nitric oxide synthase and nitric oxide-mediated apoptosis in neuronal PC12 cells after stimulation with tumor necrosis factor-alpha/lipopolysaccharide. J Neurochem. 1998 Jul; 71(1):88-94.
|
|
|
|
|
108.
|
Löschmann PA, Wüllner U, Heneka MT, Schulz JB, Kunow M, Wachtel H, Klockgether T. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease. Synapse. 1997 Aug; 26(4):381-91.
|
|
|
|
|
109.
|
Heneka MT, Löschmann PA, Osswald H. Polymerized hemoglobin restores cardiovascular and kidney function in endotoxin-induced shock in the rat. J Clin Invest. 1997 Jan 1; 99(1):47-54.
|
|
|
|
|
110.
|
Bokemeyer C, Lampe C, Heneka M, Schabet M, Bamberg M, Kanz L. Paclitaxel-induced radiation recall dermatitis. Ann Oncol. 1996 Sep; 7(7):755-6.
|
|
|
|
